LLG has received funding, consultant fees from and/or served on scientific advisory panels for Novo Nordisk, Gilead, Becton Dickinson, Sobi, Pfizer and AstraZeneca
doi: 10.1189/jlb.1111537 15 CarrollRGZasonaZGalvn-PeaSKoppeELSvinDCAngiariSet al
Obesity, diabetes, and associated comorbidities have emerged as a modern health crisis and a priority area of concern for health insurers
& Zuo, R
Lower GLP-1 drug prices are coming, but employers still need a sustainable cost strategy The Wondr Health Team As conversations about lowering GLP1 costs continue to dominate the benefits landscape, optimism is growing
COPD is evolving from an inhaler-dominated maintenance market to one increasingly shaped by targeted biologics with multiple late-stage programmes from major players converging at the same time